

To,

Date: 11.07.2023

National Stock Exchange of India Limited Exchange Plaza, Plot No C-1, Block G, BandraKurla Complex, Bandra (E) Mumbai-400051	BSE Limited P.J. Towers, Dalal Street, Mumbai – 400 001
---	---

Dear Sir/Madam,

Sub: Disclosure u/r 30 of SEBI (LO&DR) Regulations, 2015 – Cancellation of manufacturing license

With reference to the subject cited, we bring to the kind notice of the Exchange that Drugs Control Administration, Government of Telangana vide its Order dated 03.07.2023 received by the Company today i.e., on 11.07.2023 has cancelled the Company's Manufacturing License w.e.f. today for want of upgradation of manufacturing facilities, infrastructure and recruiting expert technical team as per the provisions of Schedule-M of Drugs and Cosmetics Act, 1940 & rules made there under.

Disclosure under Reg. 30 of SEBI (Listing Obligations and Disclosure Requirements) 2015 is enclosed herewith.

Thanking you.

Yours sincerely,
For Ortin Laboratories Limited



S. Murali Krishna Murthy
Managing Director

DIN: 00540632

Encl: as above

Disclosure under Reg. 30 of SEBI (Listing Obligations and Disclosure Requirements) 2015 is mentioned below:

Sl.No	Details of events that need to be provided	Information of such event(s)
1.	Name of the regulatory or licensing authority;	Drugs Control Administration, Government of Telangana
2.	Brief details of the approval/license obtained/withdrawn/ surrendered;	Cancellation of Manufacturing License.
3.	Impact/relevance of such approval/license to the listed entity;	Production will be stopped.
4.	Withdrawal/cancellation or suspension of licence/approval by the regulatory or licensing authority, with reasons for such action, estimated impact (monetary or otherwise) on the listed entity and penalty, if any	<p>Could not upgrade the manufacturing facilities, infrastructure and expert technical team as per the provisions of Schedule-M of Drugs and Cosmetics Act. 1940.</p> <p>Production of medicines is stopped and as a result there will be monetary impact to the tune of 75 percent of the turnover which is approximately Rs.6.00 crores. There is no other penalty involved or imposed on the company.</p>
5.	Period for which such approval/license is/was valid	Upto 31.12.2027
6.	Subsequently, the listed entity shall inform the stock exchange(s), the actual impact (monetary or otherwise) along with corrective actions taken by the listed entity pursuant to the withdrawal, cancellation or suspension of the key license/ approval.	<p>Production will be stopped in the present Manufacturing Unit. The company make efforts to get the medicines manufactured from other companies and would cater to the needs of the customers. Trading activities will continue in further. The company would also make serious efforts to revive the license by meeting the conditions or standards as required to be complied with for continuation of business.</p>



S. S. S.